Madrigal Pharmaceuticals (MDGL) Competitors

Madrigal Pharmaceuticals logo
$421.99 -1.97 (-0.46%)
Closing price 04:00 PM Eastern
Extended Trading
$413.39 -8.60 (-2.04%)
As of 06:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MDGL vs. GMAB, ROIV, UTHR, INCY, and INSM

Should you buy Madrigal Pharmaceuticals stock or one of its competitors? Madrigal Pharmaceuticals's main competitors and comparable companies include Genmab A/S (GMAB), Roivant Sciences (ROIV), United Therapeutics (UTHR), Incyte (INCY), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Madrigal Pharmaceuticals compare to Genmab A/S?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Genmab A/S has a net margin of 16.97% compared to Madrigal Pharmaceuticals' net margin of -10.89%. Genmab A/S's return on equity of 13.67% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals-10.89% -27.08% -12.04%
Genmab A/S 16.97%13.67%6.42%

Genmab A/S has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal Pharmaceuticals$1.43B6.85-$288.28M-$5.98N/A
Genmab A/S$3.72B8.65$963M$1.1744.05

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Madrigal Pharmaceuticals presently has a consensus target price of $706.87, suggesting a potential upside of 67.88%. Genmab A/S has a consensus target price of $53.50, suggesting a potential upside of 3.79%. Given Madrigal Pharmaceuticals' higher probable upside, equities research analysts plainly believe Madrigal Pharmaceuticals is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00

Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

In the previous week, Madrigal Pharmaceuticals had 2 more articles in the media than Genmab A/S. MarketBeat recorded 12 mentions for Madrigal Pharmaceuticals and 10 mentions for Genmab A/S. Madrigal Pharmaceuticals' average media sentiment score of 0.22 beat Genmab A/S's score of -0.09 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Genmab A/S
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Genmab A/S beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Roivant Sciences?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Madrigal Pharmaceuticals has a beta of -0.98, indicating that its share price is 198% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

In the previous week, Roivant Sciences had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 17 mentions for Roivant Sciences and 12 mentions for Madrigal Pharmaceuticals. Roivant Sciences' average media sentiment score of 0.52 beat Madrigal Pharmaceuticals' score of 0.22 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Roivant Sciences
6 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Madrigal Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal Pharmaceuticals$1.43B6.85-$288.28M-$5.98N/A
Roivant Sciences$8.26M3,302.12-$299.77M-$0.63N/A

Madrigal Pharmaceuticals presently has a consensus target price of $706.87, suggesting a potential upside of 67.88%. Roivant Sciences has a consensus target price of $46.82, suggesting a potential upside of 23.99%. Given Madrigal Pharmaceuticals' higher possible upside, equities analysts clearly believe Madrigal Pharmaceuticals is more favorable than Roivant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76
Roivant Sciences
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.79

Madrigal Pharmaceuticals has a net margin of -10.89% compared to Roivant Sciences' net margin of -838.21%. Roivant Sciences' return on equity of -22.03% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals-10.89% -27.08% -12.04%
Roivant Sciences -838.21%-22.03%-20.55%

98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Roivant Sciences beats Madrigal Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

United Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, meaning that its share price is 198% less volatile than the broader market.

United Therapeutics has a net margin of 38.61% compared to Madrigal Pharmaceuticals' net margin of -10.89%. United Therapeutics' return on equity of 19.18% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
United Therapeutics38.61% 19.18% 17.07%
Madrigal Pharmaceuticals -10.89%-27.08%-12.04%

United Therapeutics presently has a consensus target price of $676.40, indicating a potential upside of 17.16%. Madrigal Pharmaceuticals has a consensus target price of $706.87, indicating a potential upside of 67.88%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics
1 Sell rating(s)
3 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.69
Madrigal Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, United Therapeutics had 15 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 27 mentions for United Therapeutics and 12 mentions for Madrigal Pharmaceuticals. United Therapeutics' average media sentiment score of 0.83 beat Madrigal Pharmaceuticals' score of 0.22 indicating that United Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
United Therapeutics
9 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Madrigal Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

United Therapeutics has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$3.19B7.71$1.33B$26.5021.79
Madrigal Pharmaceuticals$1.43B6.85-$288.28M-$5.98N/A

Summary

United Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Incyte?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Incyte has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal Pharmaceuticals$1.43B6.85-$288.28M-$5.98N/A
Incyte$5.14B4.71$1.29B$1.8863.26

Madrigal Pharmaceuticals has a beta of -0.98, indicating that its stock price is 198% less volatile than the broader market. Comparatively, Incyte has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

In the previous week, Incyte had 5 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 17 mentions for Incyte and 12 mentions for Madrigal Pharmaceuticals. Incyte's average media sentiment score of 0.49 beat Madrigal Pharmaceuticals' score of 0.22 indicating that Incyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Incyte
6 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Madrigal Pharmaceuticals presently has a consensus price target of $706.87, indicating a potential upside of 67.88%. Incyte has a consensus price target of $132.86, indicating a potential upside of 11.72%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76
Incyte
0 Sell rating(s)
14 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.44

Incyte has a net margin of 6.71% compared to Madrigal Pharmaceuticals' net margin of -10.89%. Incyte's return on equity of 7.92% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals-10.89% -27.08% -12.04%
Incyte 6.71%7.92%6.12%

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Incyte beats Madrigal Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Madrigal Pharmaceuticals compare to Insmed?

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Madrigal Pharmaceuticals currently has a consensus target price of $706.87, indicating a potential upside of 67.88%. Insmed has a consensus target price of $196.52, indicating a potential upside of 64.91%. Given Madrigal Pharmaceuticals' higher probable upside, equities research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Insmed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Madrigal Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.76
Insmed
1 Sell rating(s)
1 Hold rating(s)
23 Buy rating(s)
1 Strong Buy rating(s)
2.92

Madrigal Pharmaceuticals has a beta of -0.98, suggesting that its share price is 198% less volatile than the broader market. Comparatively, Insmed has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 17.6% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Madrigal Pharmaceuticals had 4 more articles in the media than Insmed. MarketBeat recorded 12 mentions for Madrigal Pharmaceuticals and 8 mentions for Insmed. Insmed's average media sentiment score of 0.86 beat Madrigal Pharmaceuticals' score of 0.22 indicating that Insmed is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Madrigal Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Insmed
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Madrigal Pharmaceuticals has a net margin of -10.89% compared to Insmed's net margin of -39.85%. Madrigal Pharmaceuticals' return on equity of -27.08% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Madrigal Pharmaceuticals-10.89% -27.08% -12.04%
Insmed -39.85%-96.38%-32.55%

Madrigal Pharmaceuticals has higher revenue and earnings than Insmed. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal Pharmaceuticals$1.43B6.85-$288.28M-$5.98N/A
Insmed$606.42M43.11-$1.28B-$2.82N/A

Summary

Madrigal Pharmaceuticals beats Insmed on 9 of the 17 factors compared between the two stocks.

Get Madrigal Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDGL vs. The Competition

MetricMadrigal PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9.80B$4.03B$7.74B$11.66B
Dividend YieldN/A3.62%2.46%4.42%
P/E Ratio-70.5724.0634.1729.85
Price / Sales6.8716.218.485.62
Price / CashN/A26.3721.9322.50
Price / Book15.644.064.373.66
Net Income-$288.28M-$22.82M$3.52B$392.27M
7 Day Performance-2.45%-7.25%-5.47%-4.72%
1 Month Performance-6.17%-5.98%-4.58%-7.14%
1 Year Performance-23.75%-7.73%-1.79%-7.51%

Madrigal Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDGL
Madrigal Pharmaceuticals
4.1533 of 5 stars
$421.99
-0.5%
$706.87
+67.5%
-19.9%$9.80B$1.43BN/A915
GMAB
Genmab A/S
2.2104 of 5 stars
$55.80
+4.0%
$53.61
-3.9%
+70.4%$34.40B$3.72B39.653,029
ROIV
Roivant Sciences
2.3715 of 5 stars
$40.67
+4.6%
$46.55
+14.4%
+90.3%$27.61B$8.26MN/A721
UTHR
United Therapeutics
4.6493 of 5 stars
$582.46
+3.6%
$676.40
+16.1%
+26.0%$26.10B$3.18B21.981,400
INCY
Incyte
3.0475 of 5 stars
$121.89
+1.9%
$132.86
+9.0%
+15.5%$25.04B$5.14B64.842,844

Related Companies and Tools


This page (NASDAQ:MDGL) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners